David Thornton looks at one small Aim-listed biotech company that has the product and the management behind it to succeed.
Articles written by David Thornton
The Nasdaq’s new record high is nothing to be scared of, says David Thornton. Here, he explains why we’re not looking at a repeat of the dotcom bubble.
Early investors in Neil Woodford’s new small-cap fund could be onto a winner, says David Thornton. But as the fund’s name suggests, they must be patient.
Bigger isn’t always better when it comes to investing in companies, says David Thornton. Sometimes it pays to stay nimble.
General elections can have a big impact on investments, says David Thornton. And that’s especially true for Aim-listed stocks.
The economist John Maynard Keynes was also a very successful stock investor. Here, David Thornton outlines his three key rules for making money in the markets
The recent dismal run of Aim shares has been down largely to poor performance from resource stocks, says David Thornton. But things are starting to look up.
This tiny university spin-out company has developed two ingenious new uses for ultrasound. David Thornton looks at its prospects.
Aim-listed stock Quindell has been hauled over the coals by investors recently, says David Thornton. Is the worst now behind it?
David Thornton looks at the smaller energy companies that are turning Britain’s urgent power-shortage problem to their advantage.